Progressive Supranuclear Palsy (PSP) License Agreement

Spanish pharmaceutical company Ferrer and Swiss clinical stage biotechnology company Asceneuron have announced the signing of a licensing agreement in which Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90 in progressive supranuclear palsy (PSP), an orphan neurological disease with a high unmet medical need.

Lenz & Staehelin advised Asceneuron in this transaction. The team was led by partner Sevan Antreasyan (IP, Commercial and Contracts) and included Anne-Laure Laplace (IP, Commercial and Contracts) and Federico Trabaldo Togna (Corporate and M&A).